A Randomized Trial to Compare Dolutegravir Plus Boosted Darunavir Versus Recommended Standard of Care Antiretroviral Regimens in People With HIV-1, Whose First-line Non-nucleoside Reverse Transcriptase Inhibitor Therapy Has Failed: Final 96-week Results of the D2EFT Study. (academic.oup.com)

Authors: Nyein PP … Matthews GV Journal: Clinical Infectious Diseases Published: 2026-02-04 DOI: https://doi.org/10.1093/cid/ciaf346